Epithelial ovarian cancer (EOC) is the leading cause of death among gynecological malignancies. Despite surgery and chemotherapy, 5-years survival rates have improved only modestly over the past few decades remaining at 45% for advanced stages. Therefore, novel therapies are urgently needed. The presence of tumor-infiltrating lymphocytes (TILs) in OC tumor microenvironment (TME) has already proved to be correlated with overall survival (OS), while immune evasion mechanisms are associated with poor prognosis. Although these data indicate that immunotherapy has a strong rationale in OC, single agent immune-checkpoints inhibitors (ICIs) have shown only modest results in this malignancy. In this review, we will discuss immune-targeting combination therapies and adoptive cell therapy (ACT), highlighting the challenges represented by these strategies, which aim at disrupting the stroma-tumor barrier to boost immune system against ovarian cancer.

Ovarian cancer immunotherapy: Turning up the heat

Ghisoni E.
First
;
Valabrega G.
Last
2019-01-01

Abstract

Epithelial ovarian cancer (EOC) is the leading cause of death among gynecological malignancies. Despite surgery and chemotherapy, 5-years survival rates have improved only modestly over the past few decades remaining at 45% for advanced stages. Therefore, novel therapies are urgently needed. The presence of tumor-infiltrating lymphocytes (TILs) in OC tumor microenvironment (TME) has already proved to be correlated with overall survival (OS), while immune evasion mechanisms are associated with poor prognosis. Although these data indicate that immunotherapy has a strong rationale in OC, single agent immune-checkpoints inhibitors (ICIs) have shown only modest results in this malignancy. In this review, we will discuss immune-targeting combination therapies and adoptive cell therapy (ACT), highlighting the challenges represented by these strategies, which aim at disrupting the stroma-tumor barrier to boost immune system against ovarian cancer.
2019
20
12
2927
2942
Adoptive cell therapy; Immunotherapy; Ovarian cancer; Tumor infiltrating-lymphocytes; Tumor microenvironment; Animals; Antineoplastic Agents, Immunological; Biomarkers, Tumor; Clinical Trials as Topic; Combined Modality Therapy; Female; Humans; Immunotherapy, Adoptive; Lymphocytes, Tumor-Infiltrating; Molecular Targeted Therapy; Ovarian Neoplasms; T-Lymphocyte Subsets; Tumor Microenvironment; Immunotherapy
Ghisoni E.; Imbimbo M.; Zimmermann S.; Valabrega G.
File in questo prodotto:
File Dimensione Formato  
ijms-20-02927.pdf

Accesso aperto

Tipo di file: PDF EDITORIALE
Dimensione 616.29 kB
Formato Adobe PDF
616.29 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2318/1742204
Citazioni
  • ???jsp.display-item.citation.pmc??? 66
  • Scopus 107
  • ???jsp.display-item.citation.isi??? 99
social impact